Emery–Dreifuss muscular dystrophy

From Wikipedia, the free encyclopedia
Jump to: navigation, search
For other uses of "EDMD", see Everybody Draw Mohammed Day.
Emery–Dreifuss muscular dystrophy
X-linked recessive.svg
X-linked recessive inheritance, one of the patterns of inheritance of EDMD[1]
Classification and external resources
Specialty neurology
ICD-10 G71.0
ICD-9-CM 359.0-359.1
OMIM 181350 604929 310300
DiseasesDB

31705 33543

31704
MeSH D020389
GeneReviews

Emery–Dreifuss muscular dystrophy is a condition that mainly affects muscles used for movement, such as skeletal muscles and also affects the cardiac muscle, it is named after Alan Eglin H. Emery and Fritz E. Dreifuss.[1][2]

Classification[edit]

The types of Emery–Dreifuss muscular dystrophy are distinguished by their pattern of inheritance: X-linked, autosomal dominant, and autosomal recessive.[3]

  • Autosomal dominant Emery–Dreifuss muscular dystrophy individuals experience heart problems with weakness (and wasting) of skeletal muscles and Achilles tendon contractures.[4]
  • X-linked Emery–Dreifuss muscular dystrophy is the result of the EMD gene, with cardiac involvement and some mental retardation.[5]
  • Autosomal recessive individuals with this type of the disorder demonstrate cardiac issues, such as arrhythmia.Individuals who acquire EDMD via the autosomal recessive route have an incidence of 1 in 300,000.[6][7]

Symptoms/signs[edit]

Symptoms of EDMD begin in teenage years with toe-walking, rigid spine, face weakness, hand weakness and calf hypertrophy.[8] Among other signs/symptoms of Emery-Dreyfuss muscular dystrophy are:[3][9]

  • Muscle weakness EDMD can affect the shoulders and lower legs
  • Cardiac involvement can affect an individuals heart rate (bradycardia, palpitations)
  • Contractures of the muscles occurs slowly, eventually leading to the need for orthopedics (walker, cane)

Genetics[edit]

Protein LMNA
Protein EMD

In terms of genetics, mutations in the EMD and LMNA genes cause Emery–Dreifuss muscular dystrophy.[10] The EMD and LMNA genes provide instructions for making proteins that are components of the nuclear envelope, which surrounds the nucleus in cells. The nuclear envelope regulates the movement of molecules into and out of the nucleus, and researchers believe it may play a role in regulating the activity of certain genes.[medical citation needed]

Type OMIM Gene Description
EDMD1 310300 EMD This gene provides instructions for making a protein called emerin, a transmembrane protein of the inner nuclear membrane which appears to be essential for the normal function of skeletal and cardiac muscle. Most EMD mutations prevent the production of any functional emerin.[11][12]
EDMD2, EDMD3 181350 LMNA Emery–Dreifuss muscular dystrophy also results from mutations in the LMNA gene. This gene provides instructions for making two very similar proteins, lamin A and lamin C. Most of the LMNA mutations that cause this condition result in the production of an altered version of these proteins.[13][14]
EDMD4 612998 SYNE1 Here one finds that muscle cells indicate loss of nuclear envelope consistency, additionally the affected individual experiences cerebellar ataxia at approximately 30 years of age.[15][16]
EDMD5 612999 SYNE2 In SYNE2 we see a transition in said gene, that results in T89M as a result of a substitution. Via fluorescent in-situ hybridization the gene is located at chromosome 14q23[17]
EDMD6 300696 FHL1 This x-linked type of EDMD is had via mutations in the FHL1 gene, where protein gels (Western blots) indicate less band expression, with mutations in exon 5-8 on the gene[18][19]

Diagnosis[edit]

The diagnosis of Emery–Dreifuss muscular dystrophy can be established via single-gene testing or genomic testing, and clinically diagnosed via the following exams/methods:[3]

Treatment[edit]

The treatment (management) of Emery–Dreifuss muscular dystrophy can be done via several methods, however secondary complications should be consider in terms of the progression of EDMD, therefore cardiac defibrillators may be needed at some point by the affected individual.Other possible forms of management and treatment are the following:[3][7]

ACE inhibitor

See also[edit]

References[edit]

  1. ^ a b https://ghr.nlm.nih.gov/condition/emery-dreifuss-muscular-dystrophy#inheritance
  2. ^ Emery AE, Dreifuss FE (1966). "Unusual type of benign x-linked muscular dystrophy". J. Neurol. Neurosurg. Psychiatr. 29 (4): 338–42. doi:10.1136/jnnp.29.4.338. PMC 1064196free to read. PMID 5969090. 
  3. ^ a b c d Bonne, Gisèle; Leturcq, France; Ben Yaou, Rabah (1993-01-01). Pagon, Roberta A.; Adam, Margaret P.; Ardinger, Holly H.; Wallace, Stephanie E.; Amemiya, Anne; Bean, Lora JH; Bird, Thomas D.; Fong, Chin-To; Mefford, Heather C., eds. Emery-Dreifuss Muscular Dystrophy. Seattle (WA): University of Washington, Seattle. PMID 20301609. update 2015
  4. ^ "OMIM Entry - # 181350 - EMERY-DREIFUSS MUSCULAR DYSTROPHY 2, AUTOSOMAL DOMINANT; EDMD2". www.omim.org. Retrieved 2016-05-19. 
  5. ^ "OMIM Entry - # 310300 - EMERY-DREIFUSS MUSCULAR DYSTROPHY 1, X-LINKED; EDMD1". www.omim.org. Retrieved 2016-05-19. 
  6. ^ "OMIM Entry - # 616516 - EMERY-DREIFUSS MUSCULAR DYSTROPHY 3, AUTOSOMAL RECESSIVE; EDMD3". www.omim.org. Retrieved 2016-05-19. 
  7. ^ a b RESERVED, INSERM US14 -- ALL RIGHTS. "Orphanet: Emery Dreifuss muscular dystrophy". www.orpha.net. Retrieved 20 May 2016. 
  8. ^ "Emery-Dreifuss Muscular Dystrophy Clinical Presentation: History, Causes". emedicine.medscape.com. Retrieved 2016-05-20. 
  9. ^ "Muscular Dystrophies - An Overview. Information and advice | Patient". Patient. Retrieved 2016-05-20. 
  10. ^ Brown SC, Piercy RJ, Muntoni F, Sewry CA (December 2008). "Investigating the pathology of Emery-Dreifuss muscular dystrophy". Biochem. Soc. Trans. 36 (Pt 6): 1335–8. doi:10.1042/BST0361335. PMID 19021551. 
  11. ^ Reference, Genetics Home. "EMD". Genetics Home Reference. Retrieved 19 May 2016. 
  12. ^ "OMIM Entry - * 300384 - EMERIN; EMD". www.omim.org. Retrieved 19 May 2016. 
  13. ^ Reference, Genetics Home. "LMNA". Genetics Home Reference. Retrieved 19 May 2016. 
  14. ^ "OMIM Entry - * 150330 - LAMIN A/C; LMNA". www.omim.org. Retrieved 19 May 2016. 
  15. ^ Dupré, Nicolas; Gros-Louis, François; Bouchard, Jean-Pierre; Noreau, Anne; Rouleau, Guy A. (1 January 1993). "SYNE1-Related Autosomal Recessive Cerebellar Ataxia". GeneReviews(®). University of Washington, Seattle. Retrieved 10 May 2016. update 2011
  16. ^ "OMIM Entry - * 608441 - SPECTRIN REPEAT-CONTAINING NUCLEAR ENVELOPE PROTEIN 1; SYNE1". www.omim.org. Retrieved 19 May 2016. 
  17. ^ "OMIM Entry - * 608442 - SPECTRIN REPEAT-CONTAINING NUCLEAR ENVELOPE PROTEIN 2; SYNE2". www.omim.org. Retrieved 19 May 2016. 
  18. ^ "OMIM Entry - * 300163 - FOUR-AND-A-HALF LIM DOMAINS 1; FHL1". www.omim.org. Retrieved 19 May 2016. 
  19. ^ "OMIM Entry - # 300696 - MYOPATHY, X-LINKED, WITH POSTURAL MUSCLE ATROPHY; XMPMA". omim.org. Retrieved 19 May 2016. 

Further reading[edit]